Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALGRX 1207
- Development stage
- Discontinued
- Lead developer
- Anesiva
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ALGRX 1207 is a new chemical entity developed as a topical local anesthetic for pain management. Its primary mechanism of action is the blockade of fast sodium channels on neurons, which inhibits nerve signal transmission and provides local anesthesia. It was investigated for use in anesthesia and neuropathic pain, particularly cutaneous neuropathic pain, but development was discontinued after early clinical trials. The drug was originally developed by Anesiva (formerly Corgentech/AlgoRx Pharmaceuticals)[1][2][3][4][7].
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ALGRX 1207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALGRX 1207.